| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Pathways |
Authors' Affiliations: 1 Department of Medicine and 2 Cell Biology Program, Memorial Sloan-Kettering Cancer Center, New York, New York
Requests for reprints: Robert J. Motzer, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021. Phone: 646-422-4312; Fax: 212-988-0806; E-mail: motzerr{at}mskcc.org.
Abstract
Inheritance of a defective copy of the von Hippel-Lindau (VHL) gene leads to the most common cause of inherited renal cell carcinoma (RCC). In addition, most patients with sporadic RCC have aberrant VHL. In the absence of VHL, hypoxia-inducible factor
accumulates, leading to production of several growth factors, including vascular endothelial growth factor and platelet-derived growth factor. We review here the biology of RCC and how a combination of proximal and distal block of VHL/hypoxia-inducible factor
pathway by novel targeted agents, including sunitinib, sorafenib, bevacizumab, everolimus, and temsirolimus, has led to significant improvements in progression-free survival.
This article has been cited by other articles:
![]() |
S. S. Singhal, J. Singhal, S. Yadav, M. Sahu, Y. C. Awasthi, and S. Awasthi RLIP76: A Target for Kidney Cancer Therapy Cancer Res., May 15, 2009; 69(10): 4244 - 4251. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Arai, S. Ushijima, H. Fujimoto, F. Hosoda, T. Shibata, T. Kondo, S. Yokoi, I. Imoto, J. Inazawa, S. Hirohashi, et al. Genome-wide DNA methylation profiles in both precancerous conditions and clear cell renal cell carcinomas are correlated with malignant potential and patient outcome Carcinogenesis, February 1, 2009; 30(2): 214 - 221. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Lam, S. Bussom, and Y.-C. Cheng Effect of hypoxia on the expression of phosphoglycerate kinase and antitumor activity of troxacitabine and gemcitabine in non-small cell lung carcinoma Mol. Cancer Ther., February 1, 2009; 8(2): 415 - 423. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. E. Hutson, R. A. Figlin, J. G. Kuhn, and R. J. Motzer Targeted Therapies for Metastatic Renal Cell Carcinoma: An Overview of Toxicity and Dosing Strategies Oncologist, October 1, 2008; 13(10): 1084 - 1096. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Arai, S. Ushijima, H. Tsuda, H. Fujimoto, F. Hosoda, T. Shibata, T. Kondo, I. Imoto, J. Inazawa, S. Hirohashi, et al. Genetic Clustering of Clear Cell Renal Cell Carcinoma Based on Array-Comparative Genomic Hybridization: Its Association with DNA Methylation Alteration and Patient Outcome Clin. Cancer Res., September 1, 2008; 14(17): 5531 - 5539. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Signoretti, G. Bratslavsky, F. M. Waldman, V. E. Reuter, J. Haaga, M. Merino, G. V. Thomas, M. R. Pins, T. Libermann, J. Gillespie, et al. Tissue-Based Research in Kidney Cancer: Current Challenges and Future Directions Clin. Cancer Res., June 15, 2008; 14(12): 3699 - 3705. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Lam, C.-H. Leung, S. Bussom, and Y.-C. Cheng The Impact of Hypoxic Treatment on the Expression of Phosphoglycerate Kinase and the Cytotoxicity of Troxacitabine and Gemcitabine Mol. Pharmacol., September 1, 2007; 72(3): 536 - 544. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |